Affordable Access

Access to the full text

Multicentre, randomised, open-label, non-inferiority trial comparing the effectiveness and safety of ductal lavage versus oral corticosteroids for idiopathic granulomatous mastitis: a study protocol

  • Hu, Tingting1
  • Li, Shunrong1
  • Huang, Heng2
  • Huang, Hui3
  • Tan, Luyuan1
  • Chen, Yanbo1
  • Deng, Heran1
  • Wu, Jiannan1
  • Zhu, Liling1
  • Zhang, Jian4
  • Su, Fengxi1
  • Chen, Kai1
  • 1 Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China , Guangzhou (China)
  • 2 Lianjiang People’s Hospital, Zhanjiang, Guangdong, China , Zhanjiang (China)
  • 3 Maternity and Child Health Care Hospital of Jiangmen, Jiangmen, Guangdong, China , Jiangmen (China)
  • 4 Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China , Guangzhou (China)
Published Article
BMJ Open
Publication Date
Oct 10, 2020
DOI: 10.1136/bmjopen-2019-036643
PMID: 33039992
PMCID: PMC7552910
PubMed Central


Introduction The ideal treatment for idiopathic granulomatous mastitis (IGM) remains unclear. In a prospective, single-centre, pilot study, we reported that ductal lavage treatment for non-lactational mastitis patients had a 1-year clinical complete response (cCR) rate of >90%, without any significant adverse events. Thus, in this multicentre, randomised, open-label, non-inferiority trial, we will aim to compare the effectiveness and safety of ductal lavage vs oral corticosteroids as the first-line treatment for patients with IGM. Methods and analysis The trial will be conducted at the Breast Tumor Center of Sun Yat-sen Memorial Hospital in China and at least at one participating regional centre. We plan to recruit 140 eligible IGM patients who will be randomised into the ductal lavage group or oral corticosteroid group with a 1:1 ratio. The patients in the oral corticosteroid group will receive meprednisone or prednisone for 6 months. The patients in the ductal lavage group will receive ductal lavage and breast massage, as previously reported. All the participants will be followed up at the clinic for 1 year post randomisation. The primary endpoint of this trial will be the 1-year cCR rate, and the secondary endpoints will include the time to cCR, treatment failure rate, relapse rate and protocol compliance rate. The trial was designed to determine whether ductal lavage is non-inferior to oral corticosteroids (1-year cCR rate assumed to be 90%), with a non-inferiority margin of 15%. Ethics and dissemination The ethics committee of Sun Yat-sen Memorial Hospital at Sun Yat-sen University approved the study (2018-Lun-Shen-Yan-No. 30). The results of the trial will be communicated to the participating primary care practices, published in international journals and presented at international clinical and scientific conferences. Trial registration number Registry ( NCT03724903 ); Pre-results.

Report this publication


Seen <100 times